$KYMRIAH is indicated for the treatment of paediatric and young adult patients aged 3 to 25 years with relapsed or refractory B-cell acute lymphoblastic leukaemia and adult patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem cell transplant.$

For Health Care Professionals Outside the US

Find a Centre

Patient Identification
Treatment Process
Manufacturing

WHICH PATIENTS ARE ELIGIBLE FOR KYMRIAH?

$Consider Kymriah for patients with relapsed or refractory DLBCL who have these characteristics$ $Consider Kymriah for patients with relapsed or refractory DLBCL who have these characteristics$

PARTNERSHIP DRIVES THE CREATION OF THIS INNOVATIVE, CUSTOMISED TREATMENT

Collaboration among physicians, Novartis, and the qualified Treatment Centre is crucial to delivering this personalised treatment

Select icon below to learn more about the KYMRIAH process

1. Flexible Collection and Cryopreservation¹:

The patient’s T-cells are collected through leukapheresis, cryopreserved, and sent to the Novartis manufacturing facility

2. Manufacturing¹:

The patient’s cryopreserved cells are reengineered to recognise and attack cancer cells

Patient
Identification

5. Post-Infusion
Monitoring

1. Flexible Collection
and Cryopreservation

1. Flexible Collection and Cryopreservation¹:

The patient’s T-cells are collected through leukapheresis, cryopreserved, and sent to the Novartis manufacturing facility

2. Manufacturing

2. Manufacturing¹:

The patient’s cryopreserved cells are reengineered to recognise and attack cancer cells

4. Flexibility of Inpatient or
Outpatient Infusion

4. Flexibility of Inpatient or Outpatient Infusion¹:

The patient receives KYMRIAH during a single infusion that can be performed in an inpatient or outpatient setting

3. Specialised Shipping

3. Specialised Shipping^1,4:

Once the patient’s cells have been successfully reengineered, they are cryopreserved and sent via a special courier back to the treatment centre

5. Post-Infusion
Monitoring

5. Post-Infusion Monitoring¹:

Patients should stay within 2 hours of their treatment centre for at least 4 weeks after infusion. Daily monitoring will be required for 10 days post-infusion and can be done in either inpatient or outpatient settings. Patients should be encouraged to join the KYMRIAH registry to assist with long-term monitoring

3. Specialised Shipping^1,4:

Once the patient’s cells have been successfully reengineered, they are cryopreserved and sent via a special courier back to the treatment centre

4. Flexibility of Inpatient or Outpatient Infusion¹:

The patient receives KYMRIAH during a single infusion that can be performed in an inpatient or outpatient setting

5. Post-Infusion Monitoring¹:

For full safety information, please see the Summary of Product Characteristics.

MANUFACTURING AN INDIVIDUALISED TREATMENT ON A GLOBAL SCALE

Proven Process on a Global Scale^2,3

KYMRIAH has been studied in global clinical trials in 11 countries and 27 sites across Europe, North America, Australia, and Asia. Due to the locations of these studies, KYMRIAH can be delivered on a global scale.

Adaptable Leukapheresis⁴

Schedule collection as soon as a patient is identified, or at a time in the best interest of the patient.

Extended Storage⁴

Proactively collect cells, and store leukapheresis material for an extended period (up to 30 months) before manufacturing begins, if you decide that is the best treatment course for your patient.

NEXT: Qualified Centres

References:

Kymriah Summary of Product Characteristics. Novartis Pharma AG; 2022.
Schuster SJ, Bishop MR, Tam CS, et al. Primary analysis of JULIET: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Poster presented at: 59th American Society of Hematology Annual Meeting and Exposition; December 9-12, 2017; Atlanta, GA. Abstract 577.
Grupp SA, Maude SL, Rives S, et al. Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia. Presented at: 60th American Society of Hematology Annual Meeting; December 1-4, 2018; San Diego, CA.
Data on file. Novartis CTL019 Leukapheresis Reference Manual: leukapheresis collection. Novartis Pharmaceuticals Corp; June 2019.